Richard Nowak, MD, MS, associate professor of neurology, and director of Clinical & Translational Neuromuscular Research and the Yale Myasthenia Gravis Clinic at Yale School of Medicine

Richard Nowak, MD, MS

Reducing Steroid Burden in gMG With CD19 Targeting, with Richard Nowak, MD, MS

Inebilizumab's benefits for generalized myasthenia gravis (gMG) have been  validated by recent data from the phase 3 MINT trial (NCT04524273). In the trial, the therapy was shown. to reduce exacerbations and rescue therapy use in people with gMG, while successfully tapering steroids.

These findings were presented by principal investigator Richard Nowak, MD, MS, associate professor of neurology, and director of Clinical & Translational Neuromuscular Research and the Yale Myasthenia Gravis Clinic at Yale School of Medicine.at the Myasthenia Gravis Foundation of America (MGFA) 2025 meeting in The Hague in May.

The 238 participants in MINT included 2 subsets of patients with generalized MG, AChR+ (n = 95 each randomized to inebilizumab or placebo) and MuSK+ (n = 24 each randomized to inebilizumab or placebo) patients. Nowak and colleagues found that through week 26, inebilizumab-treated patients had a hazard ratio of 0.41 (95% CI, 0.24-0.70; 

= .001) of exacerbations compared to the placebo-treated group. Furthermore, rescue therapy was used by 8.4% of the inebilizumab-treated patients compared with 23.9% of the placebo-treated patients (

= .005). All participants were able to achieve a mean steroid dose of around 5 mg a day.

 spoke with Nowak to learn more about inebilizumab’s unique advantages in treating people with gMG and the new data support the use of CD19 targeting in the disease. He also shared his outlook on research in the space in the coming years.

"I think that in the next 5 years, we'll certainly have more from the perspective of targeted therapies, and I think we're on our way to really transform how we go about taking care of our patients with MG, and hopefully apply a more personalized or precision medicine type approach. We're not there yet today, but I think that is where we're trending towards over the next 5 or even the next decade. Most certainly, the last 5 years has been quite transformative and really quite enthusiastic. It's good to be in the myasthenia gravis research space, and I think that we are making a tremendous difference for our patients with this condition," Nowak said.

Nowak RJ, Utsugisawa K, Benatar M, et al. Myasthenia Gravis inebilizumab trial (MINT): Reduced risk of MD exacerbations, rescue therapy use, and corticosteroid burden. Presented at: MGFA 2025, The Hague, Netherlands; May 13-15.

Videos

The phase 3 MINT trial has demonstrated that inebilizumab effectively reduces exacerbations and the need for rescue therapy in patients with generalized myasthenia gravis (MG), while allowing for successful steroid tapering. The trial involved 238 participants, with significant results showing a hazard ratio of 0.41 for exacerbations in inebilizumab-treated patients compared to placebo. Additionally, only 8.4% of inebilizumab-treated patients required rescue therapy versus 23.9% in the placebo group. These findings highlight inebilizumab's potential to address unmet needs in MG treatment.

Nowak also shared his outlook on research in myasthenia gravis in the next 5 years.

Reaching for Minimal Symptom Expression in gMG With Inebilizumab, with Richard Nowak, MD, MS

New data from the phase 3 MINT trial (NCT04524273) has continued to support inebilizumab’s effect of reducing exacerbations and rescue therapy use in people with generalized myasthenia gravis (MG), while successfully tapering steroids.

These findings were presented at the Myasthenia Gravis Foundation of America (MGFA) 2025 meeting in The Hague last month by principal investigator Richard Nowak, MD, MS, associate professor of neurology, and director of Clinical & Translational Neuromuscular Research and the Yale Myasthenia Gravis Clinic at Yale School of Medicine.

The trial included 238 participants, with 2 subsets of patients with generalized MG, AChR+ (n = 95 each randomized to inebilizumab or placebo) and MuSK+ (n = 24 each randomized to inebilizumab or placebo) patients. Overall, through week 26, inebilizumab-treated patients had a hazard ratio of 0.41(95% CI, 0.24-0.70; 

= .001) of exacerbations compared to the placebo-treated group. Rescue therapy was used by 8.4% of the inebilizumab-treated patients compared with 23.9% of the placebo-treated patients (

= .005), while all patients were able to achieve a mean steroid dose of around 5 mg a day.

 spoke with Nowak to learn more about inebilizumab’s potential in addressing current unmet needs for people with generalized MG. He discussed some of the unique advantages inebilizumab offers for this population and went over data highlights from the trial.

“Only about 25% to maybe a third of individuals actually achieve [minimal symptom expression] in the currently available data that we have from trials. So, there certainly continues to be an unmet need from the perspective of adequately treating patients with generalized MG, and that’s where inibilizumab comes in,” Nowak said.

Nowak discussed some of the unique advantages inebilizumab offers for this population.

Richard Nowak, MD, MS

Articles